Literature DB >> 1501600

Multifocal motor neuropathy.

G J Parry1, A J Sumner.   

Abstract

We believe that our present understanding of these syndromes is insufficient to separate CIDP from MMN clearly and consider MMN to be a remarkably multifocal, predominantly motor variant of CIDP with the very unusual electrophysiologic feature of conduction block confined to motor axons. Further studies are clearly needed to clarify fully the relationship between CIDP and MMN and the relationship of MMN and other motor syndromes to various ganglioside antibodies.

Entities:  

Mesh:

Year:  1992        PMID: 1501600

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  5 in total

1.  Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.

Authors:  F Galban-Horcajo; A M Fitzpatrick; A J Hutton; S M Dunn; G Kalna; K M Brennan; S Rinaldi; R K Yu; C S Goodyear; H J Willison
Journal:  Eur J Neurol       Date:  2012-06-22       Impact factor: 6.089

2.  Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy.

Authors:  G Comi; S Amadio; G Galardi; R Fazio; R Nemni
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 3.  Immunoglobulin for multifocal motor neuropathy.

Authors:  Stephen Keddie; Filip Eftimov; Leonard H van den Berg; Ruth Brassington; Rob J de Haan; Ivo N van Schaik
Journal:  Cochrane Database Syst Rev       Date:  2022-01-11

Review 4.  Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants.

Authors:  Mazen M Dimachkie; Richard J Barohn; Jonathan Katz
Journal:  Neurol Clin       Date:  2013-02-16       Impact factor: 3.806

5.  Asymmetric Acquired Demyelinating Polyneuropathies: MMN and MADSAM.

Authors:  Jonathan S. Katz; David S. Saperstein
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.972

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.